35 results about "Optic nerve injury" patented technology

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and related compositions and methods, that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) in order to prevent optic nerve damage and restore vision.

According to the injectable double-layer drug sustained-release hydrogel and the preparation method and application thereof, hydrogel swelling and degradation curve and mechanical property detection shows that extrusion secondary injury to optic nerves can be avoided due to the swelling ratio ratio of 14% of inner-layer hydrogel to 10% of outer-layer hydrogel; the hydrogel precursor solution prepared by the preparation method disclosed by the invention has proper mechanical strength and adhesive force so as to cope with an in-vivo environment, has good injectability, can control the gelling time within 2 minutes, perfectly conforms to a short time window of optic nerve decompression surgery, and has extremely high clinical practical value. The problems that the serious operation risk of cerebrospinal fluid leakage during optic nerve local administration and a traditional local administration carrier lacks in-situ stability and is prone to displacement are solved, the damaged microenvironment can be cooperatively regulated and controlled, and long-acting slow release of nerve regeneration is promoted; multiple functions such as operation safety, medicine long-acting slow release, biocompatibility and operation convenience are successfully integrated, and an unprecedented effective strategy is provided for solving the clinical problem of optic nerve injury.

Disclosed in the present invention is the use of a mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection. Compared to a small extracellular vesicle with exosomes as the main component, the small intracellular nanovesicle of the present invention has a smaller particle size, a narrower particle size distribution range, and greater stability at different temperatures, and has good tissue compatibility. The small intracellular nanovesicle of the present invention can better ameliorate nerve injury or neurodegenerative diseases such as optic nerve injury, ischemic stroke and Alzheimer's disease, and has very good application and research value in the field of pharmaceuticals.

The invention discloses an exosome and optic nerve injury prognosis evaluation method and system, and relates to the field of data processing and artificial intelligence, and the method comprises the steps: carrying out the collection and prognosis grade labeling of optic nerve MRI data; carrying out adaptive processing on the three-dimensional MRI voxel data by adopting anisotropic Gaussian interpolation so as to retain a micron-sized structure of an optic nerve fiber layer; constructing a double-branch gating classification network, extracting axonal injury and fusion prognosis related features through independent branches, and training by combining a dynamic focus loss function with confidence loss; and finally, the prognosis probability distribution of the patient is output through the model. According to the method, multi-modal information can be effectively fused, tiny damage feature characterization is enhanced, and the accuracy and interpretability of prognosis evaluation are improved.

The present invention relates to the technical field of pharmaceuticals, and in particular to a class of nitric oxide (NO) donor-containing compounds or pharmaceutically acceptable salts, a preparation method therefor, a pharmaceutical composition, and a use thereof in the treatment or prevention of an ocular hypertension-related ophthalmic disease and an optic nerve injury-related disease.

The invention belongs to the field of medicines, and particularly relates to application of an RGCs activity protection component in preparation of a medicine for preventing and / or treating optic nerve injury, and the RGCs activity protection component is a compound with a structure # imgabs0 # as shown in a formula 1 and a crystal of the compound. In the formula 1, R1 to R3 are independently H or alkyl groups of C1 to C3. Researches show that the formula 1 can be used as an RGCs activity protection component, can effectively promote regeneration of injured optic nerves and improve the survival rate of optic ganglion cells after optic nerve injury, and is beneficial to prevention and / or treatment of optic nerve injury diseases caused by various causes.

The invention discloses a machine vision-assisted optic nerve injury repair state detection method, and relates to the technical field of medical informatics, and the method comprises the steps: through interaction with a front-end equipment group, determining a dual-mode image, triggering a state detector, executing multi-scale image reconstruction and A2 polarization reasoning under dual-path image feature extraction, and determining an A2 polarization probability heat map; the method comprises the following steps: evaluating a repair state, performing directional detection guidance, performing multiple rounds of detection analysis based on first-order global detection and second-order directional detection in a repair period until the repair period is finished, and generating a periodic state evolution graph, so as to solve the problems that in the prior art, the detection is one-sided, and repair associated information of different levels cannot be effectively applied; the technical problem that the detection intelligence and the accuracy of repair state evaluation are limited due to multi-modal imaging information in the prior art is solved, and the intelligent degree and the accuracy of detection can be effectively improved by adopting a systematic detection mode which can fuse multi-modal imaging information and has multi-scale analysis and intelligent reasoning capabilities.

The invention discloses a zebra fish optic nerve ligation model construction system and device, the system comprises an acquisition module, an anesthesia module, a placement platform and a ligation module, the acquisition module is used for acquiring target basic information; the anesthesia module is used for determining target anesthesia parameters according to the target basic information; performing anesthesia according to the target anesthesia parameters; the placing platform is used for placing target zebra fish; the ligation module is used for clamping sclera by using a sterile tissue clamping tool with a fine tip so as to expose optic nerves; the eyeball is lifted through a sterile tissue clamping tool, and supporting pieces are arranged on the two sides of the eyeball to expand the operation space; separating the optic nerve from the blood vessel of the eyeball through a separation tool; ligating the optic nerve through a ligature; and removing the supporting piece, and resetting the eyeball to obtain the zebra fish optic nerve ligation model. By adopting the embodiment of the invention, the zebrafish optic nerve injury and regeneration model for simulating the chronic inflammation environment can be constructed.

The present invention relates to a method for constructing an optic nerve injury model of a tropical clawed frog, a model and an application method thereof, wherein the modeling is implemented as follows: under microscopic observation, laser is used to damage the retrobulbar optic nerve of an anesthetized juvenile tropical clawed frog, thereby obtaining a tropical clawed frog optic nerve injury model; the method of using laser to damage the retrobulbar optic nerve of an anesthetized juvenile tropical clawed frog to obtain the tropical clawed frog optic nerve injury model, which is first of its kind in China and abroad, has the following advantages: the tropical clawed frog's body is transparent when young, and the laser can be directly observed, accurately focused, and quantitatively damaged; this optic nerve injury modeling method is accurate, controllable, has a high success rate, and has a low mortality rate; the tropical clawed frog's genome is highly homologous to the human genome, and its eyeball, retina, optic nerve, visual pathway tissue structure, and visual information conduction pathway are highly similar to those of humans; the tropical clawed frog's optic nerve is regenerative, which is conducive to the study of regeneration and repair mechanisms after injury, and opens up new approaches and methods for optic nerve protection research.

The invention provides saCNTF-DSF-LNP composite nanoparticles as well as a preparation method and application of the saCNTF-DSF-LNP composite nanoparticles, and particularly relates to application of the saCNTF-DSF-LNP to preparation of medicines for treating diseases related to optic nerve injury. The method comprises the following steps: S1, preparing self-amplification CNTF RNA, and naming the self-amplification CNTF RNA as saCNTF; s2, preparing lipid nano particles entrapped with the disulfiram DSF; s3, quickly adding the ethanol phase containing the disulfiram DSF-lipid mixture into the aqueous phase containing the saCNTF, and mixing, so that the nanoparticles are formed by self-assembly; s4, purifying the nano particles by using an ultrafiltration centrifugal device to obtain saCNTF-DSF-LNP; the invention provides a preparation method and application of saCNTF-DSF-LNP, the saCNTF-DSF-LNP can inhibit neuroinflammation driven by acute pyroptosis, and continuous neurotrophic support is provided for RGC survival and long-term axon regeneration; according to saCNTF-DSF-LNP, continuous expression of CNTF is achieved through saRNA, efficient targeted delivery is achieved by means of LNP so as to reduce off-target toxicity of DSF, and a new treatment strategy is provided for neuritis and degenerative diseases.

The present invention belongs to the technical fields of biomedicine and molecular biology, and specifically relates to the application of astrocyte exosomes and melatonin pretreatment in the treatment of optic nerve injury. The present invention explores the effects on retinal and visual behavioral changes in mice after ONC by establishing an ONC model and treating with exosomes derived from astrocytes (EVs) and exosomes derived from astrocytes pretreated with melatonin (MT-EVs). The results show that exosome treatment can improve the survival rate of RGCs, and at the same time, visual behavioral tests verify its certain effect on the long-term vision improvement of mice. Moreover, compared with EVs, MT-EVs have better effects, have important clinical value, and also provide new ideas for exosome transplantation therapy, so it has good practical application value.

The application discloses an injectable double-layer drug sustained-release hydrogel and a preparation method and application thereof, and relates to the field of drug sustained-release hydrogels. The swelling and degradation curve and mechanical property detection of the hydrogel show that, when the swelling rate ratio of the inner layer hydrogel to the outer layer hydrogel is 14% to 10%, the secondary damage of the optic nerve caused by extrusion can be avoided; meanwhile, the hydrogel has suitable mechanical strength and adhesion to cope with the in-vivo environment. The hydrogel precursor solution has good injectability, and the gelation time can be controlled within 2 minutes, which perfectly matches the short time window of the optic nerve decompression surgery, and has high clinical practical value. The application solves the major surgical risk of cerebrospinal fluid leakage when the optic nerve is locally administered, and solves the problems of the traditional local drug carrier, such as lack of in-situ stability and easy displacement. The application can synergistically regulate the injury microenvironment and promote the long-acting sustained-release of nerve regeneration, successfully integrates multiple functions such as surgical safety, drug long-acting sustained-release, biocompatibility and operation convenience, and provides an unprecedented effective strategy for solving the clinical problem of the optic nerve injury.

The invention belongs to the field of ophthalmic medicines, and particularly relates to application of a 9-ether-7H-furo [3, 2-g] benzopyran-7-ketone component in preparation of a medicine for protecting optic nerve injury, and the 9-ether-7H-furo [3, 2-g] benzopyran-7-ketone component is a compound of 9-ether-7H-furo [3, 2-g] benzopyran-7-ketone. The component of the benzopyran-7-ketone is a compound with a structure # imgabs0 # as shown in a formula A and at least one of pharmaceutically acceptable crystals, solvates and co-crystals of the compound. Researches show that the compound with the structure of the formula A can accidentally have RGCs protection activity and can be used for preparing medicines for treating optic nerve injury caused by various causes.

The invention relates to the field of biological medicines, in particular to a nano-drug for treating eye diseases and a preparation method and application thereof. According to the invention, myricetin is wrapped by a polymer PLGA-PEG-HA, so that the prepared nano-drug prolongs the residence time of the drug in eyes, the release cycle and bioavailability of the drug are obviously improved, and the nano-drug has a long-acting protective effect on optic nerve injury and retinal inflammation and is remarkable in curative effect; the hyaluronic acid modified nanoparticles can improve the biocompatibility and inflammation targeting ability of the drug. A suspension obtained after the nano-drug is redissolved can be injected into a vitreous body through a microsyringe, and a long-acting protection or treatment strategy is provided for treatment of optic nerve injury and retinal inflammation.

The invention discloses an application of CD8 alpha positive macrophages in treatment of optic nerve injury. In the application, optic nerve injury treatment is specifically shown as follows: the survival of retinal ganglion cells after minor optic nerve injury is promoted; improving visual function recovery after optic nerve injury of the mouse, wherein the visual function recovery comprises retina ganglion cell function, retina function and vision recovery; the product is a medicine or a test reagent. Research shows that the survival rate of retina ganglion cells (RGCs) can be improved through CD8 alpha positive macrophage treatment, meanwhile, visual behavioral detection verifies that the CD8 alpha positive macrophage has a certain effect on long-term vision improvement of mice, and compared with an existing treatment method, the CD8 alpha positive macrophage is better in effect and has important clinical value, and the CD8 alpha positive macrophage has a good application prospect. And a new thought is provided for optic nerve injury treatment, so that the method has a good practical application value.

The invention provides application of BC1618 in preparation of a central nervous system protection medicine, and belongs to the technical field of medicine. As a novel drug, the BC1618 inhibits a key component subunit FBXO48 of E3 ubiquitin ligase and further stabilizes SERBP1 so as to play a nerve protection function. The research of the invention shows that the BC1618-FBXO48-SERBP1 axis can promote the survival of retinal ganglion cells and the regeneration of axons after optic nerve injury, and delay the degeneration of axons at the same time. In addition, the nerve protection function of the BC1618 can be further applied to a Parkinson's disease model. Therefore, the BC1618 can be used as a potential medicine composition for preventing or treating and controlling nervous system development disorder related diseases, and can remarkably improve the symptoms such as neuron death, axon loss, neuron dysfunction and dyskinesia caused by central nervous system injury and diseases (such as optic nerve injury and Parkinson's disease).

The present invention relates to the technical field of medicine, and in particular relates to a class of compounds containing a nitric oxide (NO) donor or a pharmaceutically acceptable salt, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof in the treatment or prevention of ocular-hypertension-related diseases and optic nerve injury related diseases.

The invention belongs to the technical field of medicines, and particularly relates to application of a TASK-3 agonist or a TASK-3 overexpression biological product in preparation of a medicine for recovering a visual function and preventing and / or treating optic nerve injury. The TASK-3 selective agonist CHET3 disclosed by the invention can be used for inhibiting retinal ganglion cell injury induced by optic nerve extrusion, protecting the quantity of retinal ganglion cells and saving the visual function after injury. The invention also finds that the visual function of the optic nerve extrusion mouse can be recovered by specific overexpression of TASK-3 in the retinal ganglion cells. The invention provides a new treatment strategy for clinically improving the eyesight of a patient and delaying the disease progress, and has a wide application prospect in medical research and clinical practice of optic nerve injury.

The invention discloses a biological material for promoting optic nerve injury repair and a preparation method thereof.The biological material comprises a bionic nerve scaffold, a growth factor compound, an anti-inflammatory component and a light-operated neuroelectric signal guiding layer, the bionic nerve scaffold comprises a polycaprolactone-polyethylene glycol block copolymer and self-assembly neuropeptide, the growth factor compound comprises a neurosynaptic growth factor and a vascular endothelial growth factor, the anti-inflammatory component is liposome nanoparticles loaded with interleukin-10, and the light-operated neuroelectric signal guide layer is a polypyrrole film; the oriented nanofiber scaffold of polycaprolactone-polyethylene glycol and self-assembled neuropeptide is prepared by adopting a micro-fluidic spinning technology, a three-dimensional porous scaffold is formed to simulate a natural nerve bundle topological structure and guide oriented regeneration of axons, long-acting slow release is realized through gene activated growth factors, the axon extension efficiency is effectively improved, and the growth rate of the axons is increased. Through the interleukin-10 lipidosome anti-inflammatory component, the inflammation inhibition rate is increased, and secondary injury is relieved.

The invention relates to a vector containing a Plaur gene and application of the vector in nerve injury related diseases. The invention proves that the AAV virus vector is used for enhancing the expression of the Plaur gene, so that the neuronal axon regeneration capacity can be obviously enhanced, and the nerve regeneration efficiency is improved. The effect is verified in an optic nerve injury model. According to the application, a new target is provided for nerve protection and nerve regeneration, a gene therapy means is provided for nerve regeneration, and a new way is opened up for treatment of nerve injury related diseases.

The invention relates to the technical field of medicines, in particular to application of circAgtpbp1 in preparation of a medicine for treating and / or preventing optic nerve injury. The circAgtpbp1 is a circular RNA (Ribonucleic Acid), the circBase ID of the circAgtpbp1 is nucirc0004718, and the nucleotide sequence of the circAgtpbp1 is shown as SEQ ID NO: 1 (Sequence Identifier Number 1). The invention discloses the pathogenic mechanism of the circular RNA circAgtpbp1 in optic nerve injury (ONC) and the key value of the circular RNA circAgtpbp1 as a therapeutic target for the first time, and fills up a plurality of technical gaps in the field; according to the present invention, the circAgtpbp1 is subjected to specific high expression after ONC, the molecular mechanism of the circAgtpbp1 participating in the ceRNA axis of miR-3098-3p / Pdcd1 is clarified for the first time, the molecular mechanism of the circRNA for regulating optic nerve injury through the ceRNA network is clarified, the regulation of the circRNA on the retinal ganglion cell (RGC) survival or neuroinflammation reaction is revealed, the important theoretical basis and the conversion approach are provided for the development of the gene treatment strategy of the targeting circAgtpbp1-miR-3098-3p-Pdcd1 axis, and the important application prospects are provided. The method has profound scientific significance and clinical application value.

The invention belongs to the field of medicines, and particularly discloses an application of an optic nerve protective agent in preparation of a medicine for treating optic nerve injury, and the optic nerve protective agent is a compound with a formula 1 # imgabs0 # structure and a pharmaceutically acceptable crystal thereof. According to the present invention, the component represented by the formula 1 can be adopted as the optic nerve protection active component to prepare the optic nerve injury treatment drug capable of improving the survival rate and / or the regeneration capacity of the RGCs cell.

The invention relates to the technical field of medicine, in particular to a compound containing a nitric oxide (NO) donor or pharmaceutically acceptable salt, a preparation method of the compound or the pharmaceutically acceptable salt, a pharmaceutical composition of the compound or the pharmaceutically acceptable salt, and application of the compound or the pharmaceutically acceptable salt to treatment or prevention of ophthalmic intraocular hypertension related diseases and optic nerve injury related diseases.

A method for constructing a clinically-relevant large animal model of traumatic optic neuropathy, employing a goat with orbital anatomy and optic nerve structure similar to humans as a model animal, overing the defects existing in other animals as TON model animals. The target model goat is obtained by screening parameters, such as a maximum transverse diameter of a coronal plane of a body of sphenoid bone and a wall width of a sphenoid bone, thereby facilitating the exposure of an optic nerve in a optic-canal segment under a nasal endoscopic surgery and quantitative injury. With the optic nerve injury animal model, the clinical TON pathogenesis can be explored by studying the optic nerve at the injured optic canal. In the prepared TON animal model, the injured optic nerve is closer to the brain, which is beneficial to rebuilding the synaptic connection.

The invention belongs to the field of medicines, and particularly relates to application of an RGCs protective agent in preparation of a medicine for treating optic nerve injury, and the RGCs protective agent is a compound with a structure shown in a formula A # imgabs0 #. Innovative research shows that the compound in the formula A has an excellent RGCs protection effect and can be used for protecting RGCs with optic nerve injury.

The invention relates to the technical field of medicine, in particular to a compound containing a nitric oxide (NO) donor or pharmaceutically acceptable salt, a preparation method of the compound or the pharmaceutically acceptable salt, a pharmaceutical composition of the compound or the pharmaceutically acceptable salt, and application of the compound or the pharmaceutically acceptable salt to treatment or prevention of ophthalmic intraocular hypertension related diseases and optic nerve injury related diseases.

The invention relates to the technical field of biological medicine, in particular to application of inner boundary membrane digestion in the optic nerve injury repairing process. The invention finds that inner bound membrane digestion plays a positive regulation role in optic nerve injury, that is, digestion of the inner bound membrane promotes integration of transplanted RGC and host retina. And in addition, the survival and integration rate of transplanted RGC can be further improved by combining inner bound membrane digestion with microglial cell removal, so that the establishment of eye-brain connection of the transplanted RGC is promoted. Therefore, according to the invention, digestion of the inner boundary membrane is combined with microglial cell removal, so that functional repair of optic nerves is facilitated, and survival and integration of transplanted RGC are promoted.

The invention belongs to the technical field of medicines, and particularly relates to a conductive hydrogel nerve cannula and application thereof in promoting optic nerve injury reconstruction. The conductive hydrogel nerve cannula disclosed by the invention is named as Exoamp; the conductive hydrogel nerve sleeve is loaded with the engineered bone marrow mesenchymal stem cell exosome and a YAP signal activator TT-10, and the engineering bone marrow mesenchymal stem cell exosome and the YAP signal activator TT-10 are loaded on the conductive hydrogel nerve sleeve; the engineering bone marrow mesenchymal stem cell exosome is a bone marrow mesenchymal stem cell exosome entrapped with C3. The conductive hydrogel nerve cannula is subjected to three-dimensional printing based on optic nerve cross section diameter parameters obtained by MRI, and rapid and accurate individualized preparation can be achieved. In-vivo experiment results show that the conductive hydrogel nerve cannula has excellent conductive characteristics and excellent conductivity for Exoamp; due to the space-time release regulation capability of C3 / TT-10 at the injured part, RGC axon regeneration can be effectively promoted, scar formation is inhibited, and an innovative strategy with remarkable clinical application potential is provided for ONC treatment.

The invention provides application of an itaconic acid compound in preparation of a medicine for treating retinal artery occlusion, and belongs to the technical field of treatment of fundus diseases. In particular to new application of itaconic acid and derivatives thereof in preparation of drugs for treating or preventing retinal artery occlusion, the technical cognition of itaconic acid compounds in the traditional application field is broken through, a new small molecule candidate drug is provided for prevention and treatment of retinal ischemic diseases, and the application value is definite. The damage to the structure of the retina in retinal artery occlusion can be relieved, and the visual function is effectively improved; the retina microglial cells can be promoted to be polarized to M2 type, the generation of anti-inflammatory factors IL-10 and TGF beta can be increased, and a protective effect is achieved in the inflammatory response of the retina; the effect of protecting retinal ganglion cells from apoptosis is also achieved. The compound can be used for related diseases such as retinal ischemic diseases, fundus retina inflammation injury and optic nerve injury, and has a wide application prospect for fundus diseases.

This invention discloses a machine vision-assisted method for detecting the repair status of optic nerve injury, belonging to the field of medical informatics technology. The method includes: determining a bimodal image through interaction with a front-end device group, triggering a state detector, performing multi-scale image reconstruction and A2 polarization inference under dual-path image feature extraction, determining an A2 polarization probability heatmap, assessing the repair status and providing directional detection guidance, performing multiple rounds of detection analysis based on first-order global detection and second-order directional detection within the repair cycle until the end of the repair cycle, and generating a periodic state evolution map. This invention addresses the technical problem in existing technologies where detection is one-sided and fails to effectively apply repair correlation information at different levels, resulting in limited detection intelligence and accuracy of repair status assessment. By adopting a systematic detection method that can integrate multimodal imaging information and has multi-scale analysis and intelligent reasoning capabilities, the method can effectively improve the intelligence and accuracy of detection.